Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02269995

Enrollment

300

Registered

2014-10-21

Start date

2014-03-06

Completion date

2015-12-25

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular, Carcinoma

Brief summary

This surveillance's objectives are: 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Factors considered to have effect to safety and effectiveness

Interventions

DEVICEE7040

E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Patients with Hepatocellular carcinoma

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame
Safety and Tolerability as measured by Adverse Events	Up to 30 days

Secondary

Measure	Time frame
Efficacy of DC bead as assessed by embolic performance	Up to 30 days

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026